Intellect Neurosciences Inc. (fka ILNS)

[Dubb10]

I had hoped that Shire's last 10-Q provided some info on OX1/SHP622. Not much other than positive sentiment about the results from 2010.

SHP622 for the treatment of Friedreich’s Ataxia (“FA”)

SHP622 is in development for the treatment of Friedreich’s Ataxia and was acquired as part of the acquisition of ViroPharma. This product is a naturally occurring small molecular weight drug compound that prevents oxidative stress OX1 (indole-3-propionic acid) by a combination of hydroxyl radical scavenging activity and metal chelation. Phase 1 studies in healthy adults were completed in 2010. The drug was found to be generally well tolerated, and the pharmacokinetics revealed that the drug was rapidly absorbed and distributed in the body after oral administration. A Phase 1b trial of SHP622 in adults with FA is ongoing.
http://www.nasdaq.com/symbol/shpg/sec-filings